Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
June 14, 2022 09:00 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
May 25, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
May 12, 2022 07:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and...
May 10, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
May 05, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
April 25, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six...
April 19, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
April 04, 2022 07:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to...
March 21, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at Stifel 2022 CNS Days

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...